- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 21.08. | ViroGates A/S: ViroGates announces its Half-Year Report for H1 2025 | 60 | GlobeNewswire (Europe) | Company Announcement no. 10/2025 (August 21, 2025)
Revenue ending 18% below H1 2024, operating loss reduced by 26%, and proof of concept achieved for suPARnostic® POC+ in longevity
BIRKERØD, DENMARK... ► Artikel lesen | |
| 16.06. | ViroGates A/S: ViroGates and GENSPEED achieve proof of concept for their suPARnostic POC+ targeted at the Longevity Testing Market | 159 | GlobeNewswire (Europe) | Company Announcement no. 9/2025 (June 16, 2025)
BIRKERØD, DENMARK - ViroGates A/S ("ViroGates" or the "Company"), a medical technology company developing blood tests for measuring chronic inflammation... ► Artikel lesen | |
| 21.05. | ViroGates A/S: Resolutions from the Extraordinary General Meeting of ViroGates A/S | 112 | GlobeNewswire (Europe) | Company Announcement no. 8/2025 (May 21, 2025)
BIRKERØD, DENMARK - ViroGates A/S ("ViroGates" or the "Company"), a medical technology company developing blood tests for measuring chronic inflammation... ► Artikel lesen | |
| 01.05. | ViroGates A/S: ViroGates announces its Q1 report for 2025 | 84 | GlobeNewswire (Europe) | Company Announcement no. 6/2025 (May 01, 2025)
Revenue comparable to the same period last year, operating expenses reduced by 33%, and an amended agreement with Sobi
BIRKERØD, DENMARK - ViroGates A/S... ► Artikel lesen | |
| VIROGATES Aktie jetzt für 0€ handeln | |||||
| 20.03. | ViroGates A/S: ViroGates announces its Annual Report 2024 | 160 | GlobeNewswire (Europe) | Company Announcement no. 3/2025 (March 20, 2025)
Revenue declines by 12 % compared to last year as ViroGates continues the transition into the health- and longevity segment and fosters strategic partnerships
BIRKERØD... ► Artikel lesen | |
| 07.11.24 | ViroGates A/S: ViroGates announces its Interim Report for Q1-Q3 2024: Revenues are disappointing, but strategic refocusing will pave the way for future growth | 242 | GlobeNewswire (Europe) | Company Announcement no. 9/2024 (November 07, 2024)
BIRKERØD, DENMARK - ViroGates A/S ("ViroGates" or the "Company"), a medical technology company developing blood tests for the measurement of chronic... ► Artikel lesen | |
| 06.11.24 | First North Denmark: ViroGates A/S - increase | 420 | GlobeNewswire | New shares in ViroGates A/S will be admitted to trading on Nasdaq First North
Growth Market Denmark as per 8 November 2024. New shares are issued due to a
directed issue of new shares.
Name: ... ► Artikel lesen | |
| 21.10.24 | XFRA NEW INSTRUMENTS AVAILABLE ON XETRA - 21.10.2024 | 1.066 | Xetra Newsboard | The following instruments on XETRA do have their first trading 21.10.2024 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 21.10.2024
Aktien
1 AU000000ARB5 ARB Corporation Ltd.
2... ► Artikel lesen | |
| 14.10.24 | ViroGates A/S: ViroGates announces a distribution agreement with suPAR Health and a directed issue of shares to suPAR Remedy LLC | 277 | GlobeNewswire (Europe) | Company Announcement no. 8/2024 (October 14, 2024)
ViroGates announces an agreement with US-based suPAR Health to distribute its blood test for chronic inflammation within the United States. ViroGates... ► Artikel lesen |
9 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 96,05 | +7,98 % | BioNTech erreicht Phase-3-Erfolg bei Brustkrebsstudie mit BNT323 | BioNTech hat gemeinsam mit DualityBio einen wichtigen Studienerfolg erzielt: In einer von DualityBio in China durchgeführten Phase-3-Studie erreichte der Antikörper-Wirkstoff-Kandidat Trastuzumab Pamirtecan... ► Artikel lesen | |
| QIAGEN | 40,390 | +0,44 % | dpa-AFX-Überblick: UNTERNEHMEN vom 29.08.2025 - 15.15 Uhr | ROUNDUP: Gerresheimer bekommt überraschend neuen Finanzchef - Aktie erholt DÜSSELDORF - Der zuletzt schwächelnde Pharmaverpackungshersteller Gerresheimer bekommt überraschend einen neuen Finanzchef.... ► Artikel lesen | |
| EVOTEC | 5,856 | +2,70 % | Evotec Aktie: Bringt der "Insiderkauf" die große Kurs-Wende? | Ein großer "Insiderkauf" machte bei der Evotec Aktie in dieser Woche Schlagzeilen. Wer dachte, dass der Aktienkauf des CEO von Evotec im Wert von knapp 0,3 Millionen Euro aber massive Dynamik in die... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 50,79 | +4,66 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights | Aligned with FDA on del-brax accelerated and full approval pathways for FSHD, reported positive topline data from Phase 1/2 FORTITUDE trial, and initiated global... ► Artikel lesen | |
| BEAM THERAPEUTICS | 20,810 | +12,12 % | Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease | CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 25,845 | +8,57 % | Summit Therapeutics stock maintains Buy rating at H.C. Wainwright on ivonescimab progress | ||
| MOONLAKE IMMUNOTHERAPEUTICS | 59,89 | +0,28 % | MoonLake Immunotherapeutics AG: MoonLake Immunotherapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update | Phase 3 VELA program in hidradenitis suppurativa (HS) on track for an expected primary endpoint readout around September 2025 and an expected submission of a Biologic License Application (BLA) in the... ► Artikel lesen | |
| VERA THERAPEUTICS | 24,430 | +11,55 % | Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BRISBANE, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on August 4, 2025, the Compensation Committee of Vera's Board of Directors granted... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 34,920 | +5,26 % | Mineralys reports positive subgroup data for hypertension drug | ||
| CG ONCOLOGY | 33,160 | +7,31 % | CG Oncology Inc.: CG Oncology Completes Enrollment in PIVOT-006 | - Rapid enrollment underscores high unmet need in intermediate-risk non-muscle invasive bladder cancer (NMIBC) -- One of the largest randomized phase 3 studies in this patient population will encompass... ► Artikel lesen | |
| ARS PHARMACEUTICALS | 10,080 | -5,62 % | Roth/MKM initiates ARS Pharmaceuticals stock with Buy rating on neffy potential | ||
| NUVATION BIO | 3,870 | +13,32 % | Nuvation Bio To Present New Data on IBTROZI (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses | Presentations to include updated and additional Phase 2 clinical data for recently FDA-approved IBTROZI
Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the... ► Artikel lesen | |
| FORTRESS BIOTECH | 3,665 | +28,82 % | Fortress Biotech, Inc.: Fortress Biotech Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights | Fortress subsidiary Checkpoint Therapeutics acquired by Sun Pharma; Fortress received ~$28 million at closing and is eligible to receive up to an additional $4.8 million under a contingent value right... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,615 | +2,21 % | If You'd Invested $1,000 in Recursion Pharmaceuticals 4 Years Ago, Here's How Much You'd Have Today | ||
| COGENT BIOSCIENCES | 13,090 | +1,08 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Positive Top-line Results Achieving Statistical Significance Across All Primary and Key Secondary Endpoints from the SUMMIT Trial of Bezuclastinib in Patients with Non-Advanced ... | -- Patients treated with bezuclastinib showed a superior mean change in total symptom score at 24 weeks (-24.3 points vs. -15.4 points, -8.91 point placebo-adjusted difference; p=0.0002), compared... ► Artikel lesen |
Das Unternehmen VIROGATES A/S kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 1,335 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VIROGATES A/S finden Sie auf Wallstreet Online.